EMA Authorised: Ameluz (5-aminolevulinic acid hydrochloride) — Biofrontera Bioscience GmbH

View source ↗

Summary

EMA authorized Ameluz (5-aminolevulinic acid hydrochloride) by Biofrontera Bioscience for actinic keratosis and basal cell carcinoma, marking European marketing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Basal Cell Carcinoma

Drugs mentioned

• AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)

Snippet

Status: Authorised. Therapeutic area: Keratosis, Actinic;Carcinoma, Basal Cell. MAH: Biofrontera Bioscience GmbH. Decision date: 18/02/2026